Korean biopharmas active in exploring potential of predictive biomarkers
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
A genomic biomarker is a DNA or RNA characteristic that is an indicator of normal or pathogenic processes in the body.
According to industry sources on Wednesday, JW Bioscience, Genomictree, Aptamer Sciences, and WellMarker Bio are among those that are active in the development of predictive biomarkers.
JW Bioscience, a subsidiary of JW Life Science, is developing an early detection kit for pancreatic cancer based on CFB (complement factor B) and CA19-9 biomarkers, which are available to detect pancreatic cancer at an early stage with only a small amount of blood.
JW Bioscience also signed a non-exclusive licensing agreement with Immunovia, a Swedish diagnostic healthcare company, over its patented multi-biomarker (CFB, CA19-9), key to the test kit. The patent is registered in Korea, the U.S., 21 European countries, China, and Japan. JW Bioscience is also developing an early diagnosis solution for sepsis using WRS (tryptophanyl-tRNA synthetase).
Aptamer Sciences is another Korean player that has a track record in biomarker areas with its world's first aptamer-based lung cancer early diagnosis kit based on discovery platform technology for aptamers, which are nucleic acid molecules that bind to their target with high specificity and affinity.
Its kit measures the potential presence of four types of biomarkers (CA6, EGFR1, MMP7, KIT) related to the proliferation of non-small cell lung cancer and three types of immune-related biomarkers (C9, CRP, SERPINA3) in a small amount of blood serum (5 μl).
WellMarker Bio, a Korean cancer drug developer, is evaluating nine innovative oncology pipelines based on biomarkers for therapeutic response prediction that can be used to check the therapeutic efficacy ahead of actual treatment of patients.
According to the Korea Bio-Economy Research Center (KBERC), the biomarker market is estimated to grow from $57.6 billion in 2016 to $150 billion by 2023. Today’s biomarker-based treatment areas include oncology, cardiovascular disease, immune disease, and ophthalmic disease. Of these, the global biomarker market for oncology applications is expected to grow at a CAGR of 14.9 percent from $43.2 billion in 2016, reaching $110 billion in 2023.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Hyundai Motor’s Palisade SUV picked for Abu Dhabi police vehicle - Pulse by Maeil Business News Korea
- Kakao promotes Kakao Pay CEO Ryu to co-head Kakao parent with sitting CEO Yeo - Pulse by Maeil Business News Korea
- Samsung Elec and SK hynix command nearly 50% in NAND flash market in Q3 - Pulse by Maeil Business News Korea
- Korea’s comprehensive property tax bill doubled this year to record number of taxpayers - Pulse by Maeil Business News Korea
- Thai youth unemployment at new high - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- 8인치 파운드리 불황 때문에…‘영업익 반 토막’ DB하이텍 위기 언제까지
- “사망 충동 늘어”…의사 A씨, 유아인에 ‘마약류 처방’한 이유 [MK★이슈] - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이